Mind Medicine (MindMed) (MNMD -7.26%), a biopharmaceutical company developing psychedelic-inspired therapies for brain health disorders, reported its second quarter results on July 31, 2025. The company recorded a GAAP EPS loss of $0.50, wider than analyst expectations of $0.38. Operating costs rose sharply, and Net loss (GAAP) surpassed prior-year levels, reflecting significant clinical trial activity. Strong cash reserves provide a funding runway through 2027. The quarter demonstrated continued focus on a ...